Author Contributions Acquisition, analysis, or interpretation of data: Hammad Khan, Shahab Khan, Khizer Hamza, Faiza Gul, Sana Atta Ullah Drafting of the manuscript: Hammad Khan, Azra Jabin, Zain Ullah Durrani, Faiza Gul, Sana Atta Ullah, Saleem Shah Supervision: Hammad Khan Concept and design: Azra Jabin, Zain Ullah Durrani, Fahad Dayam, Muhammad Yaseen, Saleem Shah Critical review of the manuscript for important intellectual content: Shahab Khan, Khizer Hamza, Fahad Dayam, Muhammad Yaseen, Saleem Shah References 1.Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists in the treatment of obesity/metabolic syndrome, prediabetes/diabetes and non-alcoholic fatty liver diseasecurrent evidence
Antioxidant effects of resveratrol in the cardiovascular system
We need prospective studies that stratify GLP-1 agonist outcomes by baseline endogenous hormone levels, something no major clinical trial has done
As of TBD Annualized Performance Annualized Performance The performance data quoted represents past performance
This transparent model removes barriers to finding your optimal therapeutic dose on the medically established once-weekly schedule, without the pressure to rush dosing increases or experiment with non-standard frequencies
Ideal for those seeking a professional-grade skin whitening solution with long-lasting results
